ANNOUNCES DESIGN WINS FROM COMEDIA, LTD.
SANTA CLARA, Calif., — November 17, 2010 — OmniVision Technologies, Inc. (Nasdaq: OVTI), a leading developer of advanced digital imaging solutions, today announced the initiation of mass production of the ultra-compact, high-performance OV6930. With a packaged footprint of only 1.8 x 1.8 mm, the OV6930 is the ideal solution for applications favoring a small profile. It is excellently suited to serve a broad range of medical endoscopy applications, including bronchoscopy, colonoscopy, gastroscopy, OB/GYN and urology, and can facilitate development of medical devices that require an outside diameter under 2.6 mm. OmniVision also announced OV6930 design wins for two new medical device modules from Hong Kong based COMedia, Ltd.
“OmniVision’s advanced digital imaging technologies offer significant potential advantages in the development of improved medical imaging applications that enable less invasive and more precise medical procedures,” said James Lei, director of marketing for medical solutions for OmniVision. “Additionally, our advanced pixel design and proven manufacturing process keep our products affordable, allowing medical devices to be made disposable while increasing patient safety, operating room hygiene and ease-of-use for medical practitioners.”
The OV6930’s unique architecture combines ultra-low power consumption with OmniVision’s best-in-class pixel technology, OmniPixel®3-HS, enabling low-light performance of 3300 mV/lux-sec. The 1/10-inch array is capable of operating up to 30 frames per second (fps) in 400 x 400 HVGA or 60 fps in 400 x 200 resolution, providing RAW serial output. The low-voltage OV6930 allows cabling up to 14 ft.
The OV6930 will be on display at COMPAMED, November 17-19, 2010 at the Messe Düsseldorf in Düsseldorf, Germany where OmniVision will be exhibiting in Hall 8b, Stand E22.
The OV6930 is now shipping in volume to multiple customers.
Certain statements in this press release, including statements regarding the expected benefits, performance, capabilities, and potential market appeal of the OV6930 are forward-looking statements that are subject to risks and uncertainties. These risks and uncertainties, which could cause the forward-looking statements and OmniVision’s results to differ materially, include, without limitation: potential errors, design flaws or other problems with OV6930, customer acceptance, demand, and other risks detailed from time to time in OmniVision’s Securities and Exchange Commission filings and reports, including, but not limited to, OmniVision’s annual report filed on Form 10-K and quarterly reports filed on Form 10-Q. OmniVision expressly disclaims any obligation to update information contained in any forward-looking statement.